Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tivozanib |
Trade Name | Fotivda |
Synonyms | AV-951|AV951|KIL-8951|KRN 951|KRN-951 |
Drug Descriptions |
Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov). |
DrugClasses | VEGFR Inhibitor (Pan) 36 |
CAS Registry Number | 475108-18-0 |
NCIT ID | C85444 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
23814 + Tivozanib | 23814 Tivozanib | 0 | 0 |
Atezolizumab + Tivozanib | Atezolizumab Tivozanib | 0 | 1 |
Durvalumab + Tivozanib | Durvalumab Tivozanib | 0 | 1 |
Enzalutamide + Tivozanib | Enzalutamide Tivozanib | 0 | 1 |
Fluorouracil + Leucovorin + Oxaliplatin + Tivozanib | Fluorouracil Leucovorin Oxaliplatin Tivozanib | 0 | 0 |
Nivolumab + Tivozanib | Nivolumab Tivozanib | 0 | 2 |
PLX4720 + Tivozanib | PLX4720 Tivozanib | 1 | 0 |
Tivozanib | Tivozanib | 1 | 6 |